Symbols / RNAZ
RNAZ Chart
About
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 9.08M |
| Enterprise Value | 6.03M | Income | -27.13M | Sales | — |
| Book/sh | 1.71 | Cash/sh | 3.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 7 | IPO | — |
| P/E | — | Forward P/E | -16.50 | PEG | — |
| P/S | — | P/B | 5.79 | P/C | — |
| EV/EBITDA | -0.35 | EV/Sales | — | Quick Ratio | 1.02 |
| Current Ratio | 1.60 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -236.52 | EPS next Y | -0.60 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-04-15 16:00 | ROA | -232.54% |
| ROE | -17.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 916.97K |
| Shs Float | 832.42K | Short Float | 3.78% | Short Ratio | 0.25 |
| Short Interest | — | 52W High | 235.20 | 52W Low | 6.08 |
| Beta | 1.56 | Avg Volume | 259.42K | Volume | 7.63K |
| Target Price | — | Recom | None | Prev Close | $9.81 |
| Price | $9.90 | Change | 0.87% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$9.74
Latest analyst target
3. DCF / Fair value
$-180.92
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.74
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-16 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-06 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- New cancer approach uses tumor RNA to trigger immune attack in cells - Stock Titan Mon, 23 Feb 2026 13
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - PR Newswire Wed, 08 Oct 2025 07
- Technical Reactions to RNAZ Trends in Macro Strategies - Stock Traders Daily Fri, 20 Feb 2026 13
- Gainers Report: Is RNAZ forming higher highs and higher lows - Market Rally & AI Enhanced Market Trend Forecasts - baoquankhu1.vn ue, 24 Feb 2026 17
- Colorectal cancer study to test RNA drug TTX-MC138 after standard treatment - Stock Titan hu, 05 Feb 2026 08
- TransCode Therapeutics stock soars after promising glioblastoma study - Investing.com ue, 06 Jan 2026 08
- TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset - Stocktwits Wed, 08 Oct 2025 07
- All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy - Yahoo Finance Fri, 18 Apr 2025 07
- RNAZ Trading Temporarily Halted Due to Volatility Pause | RNAZ S - GuruFocus Wed, 23 Jul 2025 07
- What's Behind The Big Stock Moves? BDSX, APLM, RNAZ... - Nasdaq Wed, 21 May 2025 07
- TransCode Makes Bold Bet On Melanoma Vaccine With Polynoma Buyout - Benzinga Wed, 08 Oct 2025 07
- TransCode Therapeutics stock soars after Polynoma acquisition - Investing.com Wed, 08 Oct 2025 07
- TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering - PR Newswire ue, 25 Mar 2025 07
- (RNAZ) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily Wed, 07 Jan 2026 08
- TransCode Therapeutics Announces $10M Stock And Warrant Offering - Nasdaq Mon, 24 Mar 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.20M | -17.97M | -17.43M | -5.83M |
| TotalUnusualItems | -995.25K | 0.00 | 0.00 | -876.19K |
| TotalUnusualItemsExcludingGoodwill | -995.25K | 0.00 | 0.00 | -876.19K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -16.75M | -18.55M | -17.56M | -6.84M |
| ReconciledDepreciation | 534.86K | 516.75K | 98.61K | 42.47K |
| EBITDA | -16.19M | -17.97M | -17.43M | -6.71M |
| EBIT | -16.73M | -18.49M | -17.53M | -6.75M |
| NetInterestIncome | -623.09K | -50.61K | -11.58K | -94.41K |
| InterestExpense | 26.81K | 55.90K | 31.99K | 95.07K |
| InterestIncome | 684.00 | 5.29K | 20.41K | 664.00 |
| NormalizedIncome | -15.76M | -18.55M | -17.56M | -5.97M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -16.75M | -18.55M | -17.56M | -6.84M |
| TotalExpenses | 15.14M | 18.50M | 17.55M | 5.87M |
| TotalOperatingIncomeAsReported | -15.66M | -19.42M | -18.63M | -6.15M |
| DilutedAverageShares | 12.72K | 679.00 | 17.00 | 17.00 |
| BasicAverageShares | 12.72K | 679.00 | 17.00 | 17.00 |
| DilutedEPS | -1.32K | -27.31K | -1.03M | -402.55K |
| BasicEPS | -1.32K | -27.31K | -1.03M | -402.55K |
| DilutedNIAvailtoComStockholders | -16.79M | -18.55M | -17.56M | -6.84M |
| NetIncomeCommonStockholders | -16.79M | -18.55M | -17.56M | -6.84M |
| OtherunderPreferredStockDividend | 30.60K | 0.00 | ||
| NetIncome | -16.75M | -18.55M | -17.56M | -6.84M |
| NetIncomeIncludingNoncontrollingInterests | -16.75M | -18.55M | -17.56M | -6.84M |
| NetIncomeContinuousOperations | -16.75M | -18.55M | -17.56M | -6.84M |
| PretaxIncome | -16.75M | -18.55M | -17.56M | -6.84M |
| OtherIncomeExpense | -995.25K | -876.19K | ||
| SpecialIncomeCharges | 500.00 | 0.00 | 0.00 | -3.08K |
| GainOnSaleOfPPE | 500.00 | 0.00 | 0.00 | -3.08K |
| GainOnSaleOfSecurity | -995.75K | -873.11K | ||
| NetNonOperatingInterestIncomeExpense | -623.09K | -50.61K | -11.58K | -94.41K |
| TotalOtherFinanceCost | 596.96K | |||
| InterestExpenseNonOperating | 26.81K | 55.90K | 31.99K | 95.07K |
| InterestIncomeNonOperating | 684.00 | 5.29K | 20.41K | 664.00 |
| OperatingIncome | -15.14M | -18.50M | -17.55M | -5.87M |
| OperatingExpense | 15.14M | 18.50M | 17.55M | 5.87M |
| OtherOperatingExpenses | -524.06K | -923.03K | -1.08M | -278.33K |
| ResearchAndDevelopment | 9.71M | 12.26M | 10.23M | 2.75M |
| SellingGeneralAndAdministration | 5.95M | 7.15M | 8.40M | 3.40M |
| GeneralAndAdministrativeExpense | 5.95M | 7.15M | 8.40M | 3.40M |
| OtherGandA | 5.95M | 7.15M | 8.40M | 3.40M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 36.75K | 679.00 | 17.00 | 17.00 |
| ShareIssued | 36.75K | 679.00 | 17.00 | 17.00 |
| TotalDebt | 38.29K | 450.57K | 0.00 | |
| TangibleBookValue | -2.02M | 1.64M | 3.24M | 20.40M |
| InvestedCapital | -2.02M | 1.64M | 3.24M | 20.40M |
| WorkingCapital | 4.32M | 964.85K | 3.03M | 20.20M |
| NetTangibleAssets | -2.02M | 1.64M | 3.24M | 20.40M |
| CapitalLeaseObligations | 38.29K | 450.57K | 0.00 | |
| CommonStockEquity | -2.02M | 1.64M | 3.24M | 20.40M |
| TotalCapitalization | -2.02M | 1.64M | 3.24M | 20.40M |
| TotalEquityGrossMinorityInterest | -2.02M | 1.64M | 3.24M | 20.40M |
| StockholdersEquity | -2.02M | 1.64M | 3.24M | 20.40M |
| RetainedEarnings | -63.20M | -46.42M | -27.87M | -10.31M |
| AdditionalPaidInCapital | 61.18M | 48.06M | 31.11M | 30.71M |
| CapitalStock | 103.00 | 2.00 | 2.00 | 1.29K |
| CommonStock | 103.00 | 2.00 | 2.00 | 1.29K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 9.31M | 3.53M | 4.35M | 2.53M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 6.54M | 38.29K | 0.00 | 0.00 |
| DerivativeProductLiabilities | 6.54M | 0.00 | 0.00 | |
| NonCurrentAccruedExpenses | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 38.29K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 38.29K | 0.00 | |
| CurrentLiabilities | 2.77M | 3.49M | 4.35M | 2.53M |
| CurrentDeferredLiabilities | 25.41K | 27.06K | 0.00 | 30.53K |
| CurrentDeferredRevenue | 25.41K | 27.06K | 0.00 | 30.53K |
| CurrentDebtAndCapitalLeaseObligation | 38.29K | 412.28K | ||
| CurrentCapitalLeaseObligation | 38.29K | 412.28K | 0.00 | |
| PayablesAndAccruedExpenses | 2.71M | 3.05M | 4.35M | 2.50M |
| CurrentAccruedExpenses | 2.71M | 3.05M | 4.35M | 2.50M |
| DuetoRelatedPartiesCurrent | 0.00 | |||
| TotalAssets | 7.29M | 5.17M | 7.59M | 22.94M |
| TotalNonCurrentAssets | 201.16K | 714.26K | 208.58K | 206.27K |
| NonCurrentPrepaidAssets | 111.86K | 111.86K | 0.00 | |
| NonCurrentDeferredAssets | 0.00 | |||
| NetPPE | 89.31K | 602.40K | 208.58K | 206.27K |
| AccumulatedDepreciation | -310.81K | -263.34K | -139.86K | -41.25K |
| GrossPPE | 400.12K | 865.74K | 348.44K | 247.52K |
| OtherProperties | 37.73K | 481.69K | 247.52K | |
| MachineryFurnitureEquipment | 362.39K | 384.05K | 348.44K | 247.52K |
| CurrentAssets | 7.09M | 4.46M | 7.38M | 22.73M |
| OtherCurrentAssets | 828.22K | 1.15M | 1.50M | 1.84M |
| PrepaidAssets | 454.06K | 539.10K | 554.33K | 70.87K |
| Receivables | 0.00 | 360.23K | 0.00 | |
| OtherReceivables | 360.23K | |||
| CashCashEquivalentsAndShortTermInvestments | 5.81M | 2.77M | 4.97M | 20.83M |
| CashAndCashEquivalents | 5.81M | 2.77M | 4.97M | 20.83M |
| CashFinancial | 5.81M | 2.77M | 4.97M | 20.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.36M | -18.11M | -15.86M | -5.52M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 16.40M | 15.91M | 0.00 | 26.34M |
| CapitalExpenditure | -21.76K | -35.61K | -100.92K | -254.82K |
| InterestPaidSupplementalData | 16.63K | 32.86K | 37.12K | 17.87K |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 5.81M | 2.77M | 4.97M | 20.83M |
| BeginningCashPosition | 2.77M | 4.97M | 20.83M | 828.02K |
| ChangesInCash | 3.04M | -2.20M | -15.86M | 20.00M |
| FinancingCashFlow | 16.40M | 15.91M | 5.99K | 25.52M |
| CashFlowFromContinuingFinancingActivities | 16.40M | 15.91M | 5.99K | 25.52M |
| NetOtherFinancingCharges | -847.82K | |||
| ProceedsFromStockOptionExercised | 0.00 | 5.99K | 29.27K | |
| NetCommonStockIssuance | 16.40M | 15.91M | 0.00 | 26.34M |
| CommonStockIssuance | 16.40M | 15.91M | 0.00 | 26.34M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -21.76K | -35.61K | -100.92K | -251.82K |
| CashFlowFromContinuingInvestingActivities | -21.76K | -35.61K | -100.92K | -251.82K |
| NetPPEPurchaseAndSale | -21.76K | -35.61K | -100.92K | -251.82K |
| SaleOfPPE | 0.00 | 3.00K | ||
| PurchaseOfPPE | -21.76K | -35.61K | -100.92K | -254.82K |
| OperatingCashFlow | -13.34M | -18.07M | -15.76M | -5.27M |
| CashFlowFromContinuingOperatingActivities | -13.34M | -18.07M | -15.76M | -5.27M |
| ChangeInWorkingCapital | -351.48K | -1.08M | 1.31M | 468.07K |
| ChangeInOtherWorkingCapital | -1.65K | 27.06K | -30.53K | 30.53K |
| ChangeInOtherCurrentLiabilities | -412.28K | -424.38K | 0.00 | |
| ChangeInOtherCurrentAssets | 0.00 | -111.86K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -343.12K | -1.30M | 1.84M | 2.34M |
| ChangeInAccruedExpense | 0.00 | 55.60K | ||
| ChangeInInterestPayable | 0.00 | 55.60K | ||
| ChangeInPayable | 1.84M | 2.29M | ||
| ChangeInAccountPayable | 1.84M | 2.29M | ||
| ChangeInPrepaidAssets | 405.57K | 362.91K | -144.44K | -1.90M |
| ChangeInReceivables | 0.00 | 360.23K | -360.23K | 0.00 |
| OtherNonCashItems | 3.79K | |||
| StockBasedCompensation | 1.70M | 1.04M | 395.33K | 186.00K |
| DepreciationAmortizationDepletion | 534.86K | 516.75K | 98.61K | 42.47K |
| DepreciationAndAmortization | 534.86K | 516.75K | 98.61K | 42.47K |
| Depreciation | 534.86K | 516.75K | 98.61K | 42.47K |
| OperatingGainsLosses | 1.54M | 876.19K | ||
| GainLossOnInvestmentSecurities | 1.54M | 873.11K | ||
| GainLossOnSaleOfPPE | 0.00 | 3.08K | ||
| NetIncomeFromContinuingOperations | -16.75M | -18.55M | -17.56M | -6.84M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for RNAZ
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|